New COVID vaccines may be coming to Australia. Here's what to know about the JN.1 shots
COVID vaccines have saved over 1.4 million lives in WHO's European region. SARS-CoV-2 continues to evolve, affecting immunity. Australia has updated vaccines four times, now considering a fifth targeting JN.1. JN.1 vaccines should protect against newer subvariants like FLiRT and FLuQE. Regulatory bodies like the FDA and TGA are evaluating JN.1 vaccines, with Moderna and Pfizer's Spikevax and Comirnaty under review in Australia. Safety and efficacy data show improved immune responses against newer variants. Novavax, a protein-based vaccine, offers an alternative for those unable to receive mRNA vaccines. Challenges include vaccine uptake and quicker approval processes.
Reference News
COVID vaccines have saved over 1.4 million lives in WHO's European region. SARS-CoV-2 continues to evolve, affecting immunity. Australia has updated vaccines four times, now considering a fifth targeting JN.1. JN.1 vaccines should protect against newer subvariants like FLiRT and FLuQE. Regulatory bodies like the FDA and TGA are evaluating JN.1 vaccines, with Moderna and Pfizer's Spikevax and Comirnaty under review in Australia. Safety and efficacy data show improved immune responses against newer variants. Novavax, a protein-based vaccine, offers an alternative for those unable to receive mRNA vaccines. Challenges include vaccine uptake and quicker approval processes.